Quanterix to Participate in the Canaccord Genuity 41st Annual Growth Conference
Quanterix Corporation (NASDAQ: QTRX) announced that its Chairman and CEO, Kevin Hrusovsky, will participate in a virtual fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 12 at 12:00 p.m. ET. He will also conduct virtual meetings with institutional investors. The live webcast will be available on Quanterix's investor relations website, with replays accessible for 90 days. Quanterix focuses on digitizing biomarker analysis through its Simoa technology, enhancing early disease detection and treatment methods across various therapeutic areas.
- None.
- None.
Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced Chairman and Chief Executive Officer, Kevin Hrusovsky will participate in a virtual fireside chat discussion at the Canaccord Genuity 41st Annual Growth Conference on August 12 at 12:00 p.m. ET. Hrusovsky will also host virtual one-on-one and group meetings with institutional investors that day.
A live webcast of the conversation will be available on the investor section of the Quanterix website at https://ir.quanterix.com/investor-relations. Replays of the webcast will be available on the Quanterix website for 90 days following the conference.
About Quanterix
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005753/en/
FAQ
What is Quanterix Corporation's stock symbol?
When will Kevin Hrusovsky speak at the Canaccord Genuity 41st Annual Growth Conference?
Where can I watch the Quanterix webcast from the conference?
How long will the Quanterix conference webcast be available for replay?
What technology does Quanterix use for biomarker analysis?
